• Episode 13: Advances in MASLD and MASH
    Aug 14 2024
    Prof. Vlad Ratziu discusses the updated subclassification and nomenclature for steatotic liver disease, the therapeutic advance of resmetirom, and the future for MASLD and MASH.
    Show More Show Less
    37 mins
  • Episode 12: Defining ARDS
    Jul 5 2024
    Prof. Giacomo Grasselli takes us through the new concepts and explains why defining ARDS is such a difficult proposition.
    Show More Show Less
    16 mins
  • Episode 11: Cardiac rehabilitation in patients with frailty
    May 24 2024
    Dr. Eduard Shantsila discusses rehabilitation approaches for complex patients with heart disease and comorbid frailty, including those with cognitive vulnerability.
    Show More Show Less
    19 mins
  • Episode 10: Disease-modifying therapy for type 1 diabetes
    Feb 29 2024
    Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
    Show More Show Less
    35 mins
  • Episode 9: The gut microbiome and CAR T-cell therapy
    Feb 14 2024
    Prof. Marion Subklewe explores the interplay between the gut microbiota and the efficacy and safety of CAR T-cell therapy in people with hematologic malignancies.
    Show More Show Less
    20 mins
  • Episode 8: AI in stroke
    Jan 3 2024
    Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists in predicting patients’ clinical outcomes after stroke.
    Show More Show Less
    15 mins
  • Episode 7: A deep dive into ADAURA
    Dec 6 2023
    A conversation with Dr. Luis Paz-Ares about the key questions raised by the ADAURA trial of adjuvant osimertinib in early-stage NSCLC.
    Show More Show Less
    18 mins
  • Episode 6: OCT for coronary imaging
    Oct 16 2023
    Drs Niels Holm and Lene Andreasen explore the latest data on OCT and discuss its potential as an effective approach in PCI.
    Show More Show Less
    19 mins